Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Reply

MeSH terms

• Antineoplastic Agents, Immunological* / administration & dosage
• Antineoplastic Agents, Immunological* / adverse effects
• Biological Products / administration & dosage
• Biological Products / adverse effects
• Clonal Hematopoiesis* / genetics
• Clonal Hematopoiesis* / immunology
• Cytokine Release Syndrome / genetics
• Cytokine Release Syndrome / immunology
• Herpesvirus 4, Human / isolation & purification
• Humans
• Immunotherapy, Adoptive* / adverse effects
• Lymphoma, B-Cell* / genetics
• Lymphoma, B-Cell* / immunology
• Lymphoma, B-Cell* / therapy
• Lymphoma, B-Cell* / virology
• Lymphoma, T-Cell* / diagnosis
• Lymphoma, T-Cell* / genetics
• Lymphoma, T-Cell* / immunology
• Neoplasms, Second Primary* / diagnosis
• Neoplasms, Second Primary* / genetics
• Neoplasms, Second Primary* / immunology
• Receptors, Chimeric Antigen / immunology
• Risk